Keytruda's Price Compared to Generic Cancer Drugs
Keytruda (pembrolizumab), Merck's blockbuster immunotherapy for cancers like melanoma and lung cancer, costs far more than generic chemotherapy or targeted drugs. A typical U.S. dose (200-400 mg every 3 weeks) runs $11,000-$12,000 wholesale before discounts, with annual treatment exceeding $150,000 per patient.[1] Generic equivalents for older regimens, like cisplatin or paclitaxel used in similar cancers, cost $50-$500 per cycle—often 100-1,000 times less.[2]
Why No Direct Generic Keytruda Exists Yet
Keytruda has no approved generic or biosimilar in the U.S. as of 2024; it's protected by patents until at least 2028, with some extending to 2036.[3] Biosimilars, the closest analog for biologics like this PD-1 inhibitor, can't launch until patent expiry or settlements. For reference, the first Keytruda biosimilar trials are underway in Europe, but U.S. entry lags.[4] Check DrugPatentWatch.com for exact expiry dates and challenges: DrugPatentWatch.com - Keytruda Patents.
How Keytruda Stacks Up Against Generic Alternatives
Patients often switch to or combine with generics for cost reasons:
| Drug Type | Example | Price per Cycle (U.S. Wholesale) | Common Use Overlap |
|-----------|---------|----------------------------------|--------------------|
| Keytruda (branded) | Pembrolizumab | $11,000+ | Immunotherapy for NSCLC, melanoma |
| Generic chemo | Paclitaxel | $100-$300 | NSCLC, ovarian cancer |
| Generic targeted | Erlotinib (Tarceva generic) | $500-$1,000 | NSCLC |
| Generic immunotherapy (none direct) | N/A until biosimilars | N/A | PD-1 blockers |
Generics like these cut costs by 80-95% but may lack Keytruda's survival benefits in trials (e.g., Keytruda boosts 5-year survival to 30-50% in some NSCLC cases vs. 15-25% for chemo alone).[5]
Biosimilar Timeline and Potential Savings
Keytruda biosimilars could hit markets post-2028, slashing prices 20-40% initially (similar to Humira biosimilars dropping from $80,000 to $50,000/year).[6] Merck has settlements with biosimilar makers like Samsung Bioepis for U.S. entry around 2028. Until then, patient assistance programs or Medicare caps limit out-of-pocket to $2,000-$5,000/year for eligible U.S. patients.[7]
Real Patient Costs and Access Issues
Without insurance, Keytruda burdens patients with $150,000+ yearly; generics rarely exceed $10,000 even uninsured. Insured patients pay $0-$3,000 copays via Merck's copay cards, but generics often mean $0-$100. Shortages and prior authorizations hit generics harder, though.[8]
Sources:
[1] CMS ASP Pricing Data (2024)
[2] GoodRx/RedBook AWP (2024)
[3] DrugPatentWatch.com - Keytruda
[4] EMA Clinical Trials Register
[5] KEYNOTE-024/189 Trials (NEJM)
[6] IQVIA Biosimilar Report (2023)
[7] Merck Access Program
[8] Kaiser Family Foundation Oncology Report (2024)